Skip to main content

Table 1 Comparisons of clinicopathological variables and semi-quantitative parameters on 18F-FDG PET/CT between c-Met positive and negative patients

From: Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET

Variables Number (n = 61) c-Met expression P-values
Positive Negative
Gender
 Male 41 (67.2%) 20 (60.6%) 21 (75.0%) 0.233
 Female 20 (32.8%) 13 (39.4%) 7 (25.0%)  
Median age (range) 62 (36–81) 61 (36–74) 64 (38–81) 0.541#
Pathological types
 WDA 17 (27.9%) 12 (36.4%) 5 (17.9%) 0.373†
 MDA 18 (29.5%) 9 (27.3%) 9 (32.1%)  
 PDA 21 (34.4%) 9 (27.3%) 12 (42.9%)  
 MAC/SRC 5 (8.2%) 3 (9.1%) 2 (7.1%)  
Lauren classifications
 Intestinal 23 (46.9%) 13 (48.1%) 10 (45.5%) 0.851†
 Non-intestinal 26 (53.1%) 14 (51.9%) 12 (54.5%)  
Baseline CEA (ng/ml)
 Median (range) 2.9 (0.4–776.4) 2.9 (0.4–776.4) 3.1 (1.1–242.0) 0.399#
Baseline CA19–9 (U/ml)    
 Median (range) 9.0 (0.6–597.4) 8.4 (0.6–597.4) 10.1 (0.6–69.2) 0.510#
Baseline CA72–4 (U/ml)
 Median (range) 2.8 (0.8–131.2) 3.2 (0.8–131.2) 2.0 (0.9–79.3) 0.288#
Findings on PET/CT
 Locoregional 26 (42.6%) 11 (33.3%) 15 (53.6%) 0.111
 Distant metastasis 35 (57.4%) 22 (66.7%) 13 (46.4%)  
SUVmax (mean ± SD) 8.8 ± 6.40 9.6 ± 7.40 8.0 ± 4.91 0.335*
SUVpeak (mean ± SD) 7.2 ± 5.22 7.7 ± 5.99 6.6 ± 4.08 0.438*
MTV (mL, mean ± SD) 57.4 ± 54.39 70.8 ± 53.11 41.1 ± 52.32 0.034*
TLG (g, mean ± SD) 328.2 ± 417.44 428.4 ± 442.95 205.7 ± 354.40 0.039*
PFS, Median (95%CI) 14.5 (2.0–82.2) 11.5 (7.8–15.2) 17.6 (15.1–20.1) 0.039
OS, Median (95%CI) 20.0 (5–86.2) 17.0 (13.9–20.5) 24.3 (17.0–31.6) 0.043
  1. Note. SD standard deviation, CA19–9 carbohydrate antigen 19–9, CA72–4 carbohydrate antigen 72–4, CEA carcinoembryonic antigen, WDA well differentiated adenocarcinoma, MDA moderate differentiated adenocarcinoma, PDA poorly differentiated adenocarcinoma, SRC signet-ring cell carcinoma, MAC mucinous adenocarcinoma, PET/CT positron emission tomography/computed tomography, SUV standardized uptake value, Max maximum, MTV metabolic tumor volume, TLG total lesion glycolysis, PFS progression free survival, OS overall survival. *, Student’s t test; †, Chi square test; ‡, Kaplan-Meier analysis with the log-rank test; #, Mann-Whitney U test
\